non glp 1 weight loss medication WLP-1: Oral GLP-1 Support Daily GLP-1 Support – Midi

All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners

doi: 10.2337/diab.46.5.824

[DOI] [PubMed] [Google Scholar] 140

Although semaglutide (Ozempic, Wegovy) and other GLP-1 drugs have rapidly become infamous for a wide variety of common side effects, from diarrhea to Ozempic face, the most prominent warnings on their official U.S

Limitations of Clinical Trials (relevant for setting expectations): Highly selected participants (extensive exclusion criteria) Regular monitoring and support (monthly visits) Free medication (eliminates cost/access barriers) Intensive lifestyle interventions (may exceed real-world adherence) Short duration (68-72 weeks) relative to chronic disease treatment needs Real-World Studies Findings : According to real-world evidence published in peer-reviewed journals examining semaglutide and tirzepatide use in routine clinical practice: Weight loss magnitude is generally lower than clinical trial averages Discontinuation rates are often higher due to side effects, cost, or access issues Adherence rates vary widely (50-80% at 12 months in various studies) Weight regain after discontinuation is common Cardiovascular and metabolic benefits are observed even with modest weight loss Clinical Data Interpretation: Clinical trial results represent average outcomes under ideal conditions

This highlights that there could be more potential opportunities around positive allosteric modulation of the GLP-1 receptor